FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Moti Kashyap

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Tumor Cells, Cultured

Procedures

Drug Therapy, Combination

Co-author Network

Publications

TOP 3
Vaijinath S Kamanna; Shobha H Ganji; Moti L Kashyap
Recent advances in niacin and lipid metabolism.
Hamid Moradi; Hamid M Said; Nosratola D Vaziri; Moti L Kashyap; Kamyar Kalantar-Zadeh
Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword.
Shucun Qin; Linhua Zhang; Jack H Lai; Tianjiao Liu; William W Bachovchin; Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Moti Kashyap (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vaijinath S Kamanna; Shobha H Ganji; Moti L Kashyap
Recent advances in niacin and lipid metabolism.
Current opinion in lipidology 2013;24(3):239-45.
2013: Hamid Moradi; Hamid M Said; Nosratola D Vaziri; Moti L Kashyap; Kamyar Kalantar-Zadeh
Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2013;23(3):203-6.
2012: Shucun Qin; Linhua Zhang; Jack H Lai; Tianjiao Liu; William W Bachovchin; Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
Journal of cardiovascular pharmacology and therapeutics 2012;17(3):334-43.
2012: Lin-Hua Zhang; Xi-Ming Xiong; Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells.
Journal of lipid research 2012;53(5):941-50.
2011: Eliot A Brinton; Moti L Kashyap; Anthony N Vo; Roopal B Thakkar; Ping Jiang; Robert J Padley
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2011;11(3):179-87.
2010: Lin-Hua Zhang; Vaijinath S Kamanna; Shobha H Ganji; Xi-Ming Xiong; Moti L Kashyap
Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.
Journal of lipid research 2010;51(8):2211-22.
2009: Vaijinath S Kamanna; Shobha H Ganji; Moti L Kashyap
The mechanism and mitigation of niacin-induced flushing.
International journal of clinical practice 2009;63(9):1369-77.
2009: Peter H Jones; Michael H Davidson; Moti L Kashyap; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Atherosclerosis 2009;204(1):208-15.
2009: Roopal B Thakkar; Moti L Kashyap; Andrew J Lewin; Scott L Krause; Ping Jiang; Robert J Padley
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2009;9(2):69-79.
2008: Anthony N Vo; Moti L Kashyap
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Expert review of cardiovascular therapy 2008;6(10):1303-10.
2008: Shucun Qin; Takafumi Koga; Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Metabolism: clinical and experimental 2008;57(7):973-9.
2008: Vaijinath S Kamanna; Anthony Vo; Moti L Kashyap
Nicotinic acid: recent developments.
Current opinion in cardiology 2008;23(4):393-8.
2008: Lin-Hua Zhang; Vaijinath S Kamanna; Michael C Zhang; Moti L Kashyap
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.
Journal of lipid research 2008;49(6):1195-201.
2008: Vaijinath S Kamanna; Moti L Kashyap
Mechanism of action of niacin.
The American journal of cardiology 2008;101(8A):20B-26B.
2008: Richard H Karas; Moti L Kashyap; Robert H Knopp; Laurence H Keller; Daiva Regina Bajorunas; Michael H Davidson
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2008;8(2):69-81.
2007: Vaijinath S Kamanna; Moti L Kashyap
Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
The American journal of cardiology 2007;100(11 A):S53-61.
2007: Hamid M Said; Svetlana M Nabokina; Krishnaswamy Balamurugan; Zainab M Mohammed; Cecilia Urbina; Moti L Kashyap
Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes.
American journal of physiology. Cell physiology 2007;293(6):C1773-8.
2007: Shucun Qin; Tianjiao Liu; Vaijinath S Kamanna; Moti L Kashyap
Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(11):2428-34.
2007: James M McKenney; Peter H Jones; Harold E Bays; Robert H Knopp; Moti L Kashyap; Gary E Ruoff; Mark E McGovern
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Atherosclerosis 2007;192(2):432-7.
2007: C Daniel Meyers; Paul Liu; Vaijinath S Kamanna; Moti L Kashyap
Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush.
Atherosclerosis 2007;192(2):253-8.
2006: C Daniel Meyers; Madeline McCarren; Nathan D Wong; Carlos Abraira; William C Duckworth; Moti L Kashyap
Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).
The American journal of cardiology 2006;98(1):63-5.
2005: Charles Daniel Meyers; Nathan Wong; Moti L Kashyap
Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials.
Future cardiology 2005;1(4):461-71.
2005: C Daniel Meyers; Moti L Kashyap
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Current opinion in cardiology 2005;20(4):307-12.
2005: Svetlana M Nabokina; Moti L Kashyap; Hamid M Said
Mechanism and regulation of human intestinal niacin uptake.
American journal of physiology. Cell physiology 2005;289(1):C97-103.
2004: Yong S K Moon; Moti L Kashyap
Pharmacologic treatment of type 2 diabetic dyslipidemia.
Pharmacotherapy 2004;24(12):1692-713.
2004: C Daniel Meyers; Vaijinath S Kamanna; Moti L Kashyap
Niacin therapy in atherosclerosis.
Current opinion in lipidology 2004;15(6):659-65.
2004: Shobha H Ganji; S Tavintharan; Daming Zhu; Yiding Xing; Vaijinath S Kamanna; Moti L Kashyap
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.
Journal of lipid research 2004;45(10):1835-45.
2004: C Daniel Meyers; Moti L Kashyap
Management of the metabolic syndrome-nicotinic acid.
Endocrinology and metabolism clinics of North America 2004;33(3):557-75, vii.
2004: C Daniel Meyers; Moti L Kashyap
Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
Current opinion in cardiology 2004;19(4):366-73.
2003: Shaista Malik; Moti L Kashyap
Niacin, lipids, and heart disease.
Current cardiology reports 2003;5(6):470-6.
2003: Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Niacin and cholesterol: role in cardiovascular disease (review).
The Journal of nutritional biochemistry 2003;14(6):298-305.
2003: Shaista Malik; Moti L Kashyap
Dyslipidemia treatment: current considerations and unmet needs.
Expert review of cardiovascular therapy 2003;1(1):121-34.
2003: Harold E Bays; Carlos A Dujovne; Mark E McGovern; T Eric White; Moti L Kashyap; A Gene Hutcheson; John R Crouse
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
The American journal of cardiology 2003;91(6):667-72.
2003: Moti L Kashyap; S Tavintharan; Vaijinath S Kamanna
Optimal therapy of low levels of high density lipoprotein-cholesterol.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2003;3(1):53-65.
2002: Yong S K Moon; Moti L Kashyap
Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Expert opinion on pharmacotherapy 2002;3(12):1763-71.
2002: Daming Zhu; Shobha H Ganji; Vaijinath S Kamanna; Moti L Kashyap
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells.
Atherosclerosis 2002;164(2):221-8.
2002: Moti L Kashyap; Mark E McGovern; Kathleen Berra; John R Guyton; Peter O Kwiterovich; Wayne L Harper; Phillip D Toth; Laurence K Favrot; BORIS KERZNER; Stephen D Nash; Harold E Bays; Phillip D Simmons
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
The American journal of cardiology 2002;89(6):672-8.
2001: T Sakai; Vaijinath S Kamanna; Moti L Kashyap
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(11):1783-9.
2001: S Tavintharan; Moti L Kashyap
The benefits of niacin in atherosclerosis.
Current atherosclerosis reports 2001;3(1):74-82.
2000: John R Guyton; Michael A Blazing; J Hagar; Moti L Kashyap; Robert H Knopp; James M McKenney; D T Nash; S D Nash
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Archives of internal medicine 2000;160(8):1177-84.
2000: T Sakai; F Y Jin; Vaijinath S Kamanna; Moti L Kashyap
Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): additive effects of oleate-albumin complex.
Atherosclerosis 2000;149(1):43-9.
2000: Vaijinath S Kamanna; Moti L Kashyap
Mechanism of action of niacin on lipoprotein metabolism.
Current atherosclerosis reports 2000;2(1):36-46.
1999: F Y Jin; Vaijinath S Kamanna; Moti L Kashyap
Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(4):1051-9.
1998: Moti L Kashyap
Mechanistic studies of high-density lipoproteins.
The American journal of cardiology 1998;82(12A):42U-48U; discussion 85U-86U.
1998: F Y Jin; Vaijinath S Kamanna; Moti L Kashyap
Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(6):999-1006.
1997: F Y Jin; Vaijinath S Kamanna; Moti L Kashyap
Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(10):2020-8.
1996: G M Shah; Z L Lin; Vaijinath S Kamanna; Rama Pai; Babu V Bassa; F Y Jin; Daeyoung D Roh; Moti L Kashyap; MA Kirschenbaum
Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism.
Kidney international 1996;50(6):2079-87.
1996: F Y Jin; Vaijinath S Kamanna; M Y Chuang; K Morgan; Moti L Kashyap
Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).
Arteriosclerosis, thrombosis, and vascular biology 1996;16(8):1052-62.
1995: T C Rothwell; Vaijinath S Kamanna; F Y Jin; E Koren; T Foley; Moti L Kashyap
Characterization of a monoclonal antibody (HB-22) and development of an ELISA for human apolipoprotein A-I.
Clinical chemistry 1995;41(8 Pt 1):1150-8.
1994: Vaijinath S Kamanna; Moti L Kashyap; Rama Pai; D T Bui; F Y Jin; Daeyoung D Roh; G M Shah; MA Kirschenbaum
Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line.
Journal of the American Society of Nephrology : JASN 1994;5(2):193-200.